ECCMID data reinforces AstraZeneca’s commitment to transform protection for the most vulnerable by advancing science in vaccines and immune therapies
First in vitro data on AZD3152 shows the investigational COVID-19 long-acting antibody neutralises all known variants of concern identified to date.AstraZeneca will highlight new data across its Vaccines and Immune Therapies portfolio at the 33[rd] European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), 15 – 18 April 2023, reinforcing its ambition to provide long-lasting immunity for millions of people globally. The company will present 15 abstracts, including four oral presentations, at the event. Data featuring AZD3152, AstraZeneca’s investigational long-acting COVID-